Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01205581 · ClinicalTrials.gov registry record · Phase 2
Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV
A Phase 2 study, sponsored by St. Jude Children's Research Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 85
- Enrollment target
NCT01205581 is a Phase 2 study that has completed, run by St. Jude Children's Research Hospital. The registered enrollment target is 85 participants.
The verdict
NCT01205581, a Phase 2 study, has completed, sponsored by St. Jude Children's Research Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 85 participants
- Enrollment target
Study Summary
This is an open label-study of Fluzone HD, a high-dose form of trivalent, inactivated influenza vaccine (TIV), vs. Fluzone, a standard-dose form of TIV. Subjects with cancer or HIV will be vaccinated twice with one of the two vaccines and evaluated for development of immune responses.
Interventions
- BIOLOGICAL Fluzone High Dose Vaccine
- BIOLOGICAL Fluzone Standard Dose Vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01205581
The ClinicalTrials.gov registry entry for NCT01205581 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is St. Jude Children's Research Hospital, which has 410 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Fluzone High Dose Vaccine is the first listed.
NCT01205581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01205581 about?
NCT01205581 is a clinical study titled "Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV". This is an open label-study of Fluzone HD, a high-dose form of trivalent, inactivated influenza vaccine (TIV), vs. Fluzone, a standard-dose form of TIV. Subjects with cancer or HIV will be vaccinated twice with one of the two vaccines and evaluated for development of immune responses.
What is the current status of trial NCT01205581?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 85 participants. The study started on 2010-09. Estimated completion is 2013-08.
What interventions are being tested in trial NCT01205581?
The interventions under investigation include: Fluzone High Dose Vaccine (BIOLOGICAL), Fluzone Standard Dose Vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01205581?
This trial is sponsored by St. Jude Children's Research Hospital, which has 410 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.